Anaheim Bio raises €40M
Anaheim Bio announced a Series A round of €40M on 5 November 2026. The company operates in HealthTech and is based in Netherlands. Announced 5 days ago.
Outreach angles
- -Anaheim Bio launched as a preclinical-stage biotech spun out of Alesta Therapeutics.
- -The oversubscribed €40M Series A funds ANA-1, a small molecule candidate for calcium pyrophosphate deposition disease, expected to enter the clinic in 2027.
- -The board includes representatives of Droia Ventures, Frazier Life Sciences and Novartis Venture Fund; the company is based in Leiden.
Signals
Series AHealthcareDeep TechRegulated Industry
Round details
Company: Anaheim Bio
Domain: anaheim bio
Amount: €40M
Stage: Series A
Industry: HealthTech
Country: Netherlands
Announced: 5 November 2026
Other HealthTech raises
Recently funded in Netherlands